This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin ...
Source: Journal of Diabetes and Its Complications - September 18, 2016 Category: Endocrinology Authors: Niki Katsiki, Dimitri P Mikhailidis Source Type: research